Literature DB >> 10693654

A novel peptide aldehyde with activity against human cytomegalovirus in two different in vivo models.

O Weber1, J Reefschläger, H Rübsamen-Waigmann, S Raddatz, M Hesseling, D Häbich.   

Abstract

Novel peptide aldehydes (PAs) were identified as potent inhibitors of human cytomegalovirus (HCMV) in vitro. Although these compounds were highly effective against HCMV, they did not exhibit any activity against murine cytomegalovirus (MCMV). The purpose of this study was to test the antiviral activity of PA 8 as a representative of this novel class of inhibitors against HCMV in vivo. Because of the strict species specificity of HCMV we had to use two artificial animal models. In the first model, HCMV-infected human cells were entrapped into agarose plugs and transplanted into mice. In the second model, SCID mice were transplanted with human tissues that were subsequently infected with a clinical isolate of HCMV. In these two models the antiviral activity of PA 8 was clearly demonstrated, ganciclovir only being slightly superior in its in vivo antiviral activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10693654     DOI: 10.1177/095632020001100105

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  3 in total

1.  Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections.

Authors:  Earl R Kern; Deborah J Bidanset; Caroll B Hartline; Zhaohua Yan; Jiri Zemlicka; Debra C Quenelle
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir.

Authors:  Earl R Kern; Deborah J Collins; W Brad Wan; James R Beadle; Karl Y Hostetler; Debra C Quenelle
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

3.  A model of human cytomegalovirus infection in severe combined immunodeficient mice.

Authors:  Fernando J Bravo; Rhonda D Cardin; David I Bernstein
Journal:  Antiviral Res       Date:  2007-07-10       Impact factor: 5.970

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.